3′,4′-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Khong, Fay Lin ^a   Zhang, Yuan ^a   Edgley, Amanda J ^a   Qi, Weier ^a   Connelly, Kim A ^a,d   Woodman, Owen L ^c   Krum, Henry ^e   Kelly, Darren J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c RMIT UNIVERSITY   (Australia)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3',4' DIHYDROXYFLAVONOL; FLAVONOL DERIVATIVE; UNCLASSIFIED DRUG; 3',4'-DIHYDROXYFLAVONOL; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DRUG EFFECT; HEART CATHETERIZATION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIMARY PREVENTION; RAT; STREPTOZOCIN DIABETES; ANIMAL; AUTORADIOGRAPHY; DIABETIC CARDIOMYOPATHY; ECHOCARDIOGRAPHY; EXPERIMENTAL DIABETES MELLITUS; HEART LEFT VENTRICLE FUNCTION; HOMOZYGOTE; IN SITU HYBRIDIZATION; METABOLISM; TRANSGENIC RAT;

ANIMALIA; RATTUS;

ANIMALS; ANTIOXIDANTS; AUTORADIOGRAPHY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FLAVONOLS; HEART CATHETERIZATION; HOMOZYGOTE; IN SITU HYBRIDIZATION; MALE; NADPH OXIDASE; OXIDATIVE STRESS; RATS; RATS, TRANSGENIC; REACTIVE OXYGEN SPECIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79960925616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022777     Document Type: Article

References (58)

1. Bell DSH, (2003) Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26: 2433-2441.
2. Kannel WB, McGee DL, (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59: 8-13.
3. Hayat SA, Patel B, Khattar RS, Malik RA, (2004) Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci 107: 539-557.
4. Francis GS, (2001) Diabetic cardiomyopathy: fact or fiction? Heart 85: 247-248.
5. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, et al. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 20: 595-602.
6. van Heerebeek L, Borbely A, Niessen HWM, Bronzwaer JGF, van der Velden J, et al. (2006) Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure. Circulation 113: 1966-1973.
7. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, et al. (2008) Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension. Circulation 117: 43-51.
8. Brownlee M, (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
9. Dhalla NS, Liu X, Panagia V, Takeda N, (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40: 239-247.
10. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JFJ, et al. (2003) Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. Am J Physiol 285: H2392-H2398.
11. Pacher P, Szabo C, (2006) Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 6: 136-141.
12. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel J-L, et al. (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164-2171.
13. Wold LE, Ceylan-Isik AF, Ren J, (2005) Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 26: 908-917.
14. Murdoch CE, Grieve DJ, Cave AC, Looi YH, Shah AM, (2006) NADPH oxidase and heart failure. Curr Opin Pharmacol 6: 148-153.
15. Dworakowski R, Anilkumar N, Zhang M, Shah A, (2006) Redox signaling involving NADPH oxidase-derived reactive oxygen species. Biochem Soc Trans 34: 960-964.
16. Ceriello A, (2003) New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy. Diabetes Care 26: 1589-1596.
17. Pietta P-G, (2000) Flavonoids as antioxidants. J Nat Prod 63.
18. Burda S, Oleszek W, (2001) Antioxidant and antiradical activities of flavonoids. J Agric Food Chem 49: 2774-2779.
19. Woodman OL, Chan ECH, (2004) Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 31: 786-790.
20. Wang S, Dusting GJ, May CN, Woodman OL, (2004) 3[prime],4[prime]-Dihydroxyflavonol reduces infarct size and injury associated with myocardial ischaemia and reperfusion in sheep. Br J Pharmacol 142: 443-452.
21. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, et al. (2007) Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 76: 280-291.
22. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, et al. (2009) Inhibition of Protein Kinase C-{beta} by Ruboxistaurin Preserves Cardiac Function and Reduces Extracellular Matrix Production in Diabetic Cardiomyopathy. Circ Heart Fail 2: 129-137.
23. Bunag RD, (1973) Validation in awake rats of a tail cuff method for measuring systolic pressure. J Appl Physiol 34: 279-282.
24. Pfeffer JM, Pfeffer MA, Frohlich ED, (1971) Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 78: 957-962.
25. Tan SM, Zhang Y, Cox AJ, Kelly DJ, Qi W, (2010) Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy. Nephrol Dial Transplant In Press.
26. Advani A, Gilbert RE, Thai K, Gow RM, Langham RG, et al. (2009) Expression, Localization, and Function of the Thioredoxin System in Diabetic Nephropathy. J Am Soc Nephrol 20: 730-741.
27. Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ, (2010) Targeted inhibition of activin receptor-like kinase 5 (ALK5) signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 298: H1415-H1425.
28. Fang ZY, Prins JB, Marwick TH, (2004) Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications. Endocr Rev 25: 543-567.
29. Bollano E, Omerovic E, Svensson H, Waagstein F, Fu M, (2007) Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. Int J Cardiol 114: 195-201.
30. Privratsky JR, Wold LE, Sower JR, Quinn MT, Ren J, (2003) AT1 Blockade Prevents Glucose-Induced Cardiac Dysfunction in Ventricular Myocytes: Role of the AT 1 Receptor and NADPH Oxidase. Hypertension 42: 206-212.
31. Giacchetti G, Sechi LA, Rilli S, Carey RM, (2005) The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16: 120-126.
32. Grassi D, Desideri G, Croce G, Tiberti S, Aggio A, et al. (2009) Flavonoids, Vascular Function and Cardiovascular Protection. Curr Pharm Des 15: 1072-1084.
33. Nijveldt RJ, van Nood E, van Hoorn DEC, Boelens PG, van Norren K, et al. (2001) Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74: 418-425.
34. Ago T, Sadoshima J, (2006) Thioredoxin and ventricular remodeling. J Mol Cell Cardiol 41: 762-773.
35. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, et al. (2004) Hyperglycemia Promotes Oxidative Stress through Inhibition of Thioredoxin Function by Thioredoxin-interacting Protein. J Biol Chem 279: 30369-30374.
36. Chen J, Cha-Molstad H, Szabo A, Shalev A, (2009) Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am J Physiol Endocrinol Metab 296: E1133-1139.
37. Qi W, Chen X, Gilbert RE, Zhang Y, Waltham M, et al. (2007) High Glucose-Induced Thioredoxin-Interacting Protein in Renal Proximal Tubule Cells Is Independent of Transforming Growth Factor-{beta}1. Am J Pathol 171: 744-754.
38. Xia Z, Guo Z, Nagareddy PR, Yuen V, Yeung E, et al. (2006) Antioxidant N-acetylcysteine restores myocardial Mn-SOD activity and attenuates myocardial dysfunction in diabetic rats. Eur J Pharmacol 544: 118-125.
39. Limaye PV, Raghuram N, Sivakami S, (2003) Oxidative stress and gene expression of antioxidant enzymes in the renal cortex of streptozotocin-induced diabetic rats. Mol Cell Biochem 243: 147-152.
40. Yamakura F, Kawasaki H, Post-translational modifications of superoxide dismutase. Biochimica et Biophysica Acta (BBA)- Proteins & Proteomics 1804: 318-325.
41. Alvarez B, Demicheli V, Duran R, Trujillo M, Cervenansky C, et al. (2004) Inactivation of human Cu,Zn superoxide dismutase by peroxynitrite and formation of histidinyl radical. Free Radic Biol Med 37: 813-822.
42. White V, Capobianco E, Higa R, Martinez N, Sosa M, et al. (2010) Increased nitration and diminished activity of copper/zinc superoxide dismutase in placentas from diabetic rats. Free Radic Res 44: 1407-1415.
43. Aliciguzel Y, Ozen I, Aslan M, Karayalcin U, (2003) Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 142: 172-177.
44. Gilbert RE, Connelly K, Kelly DJ, Pollock CA, Krum H, (2006) Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes. Clin J Am Soc Nephrol 1: 193-208.
45. Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, et al. (2007) Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients: Reversal by chronic angiotensin II type 1A receptor blocker. Circ J 71: 524-529.
46. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, et al. (2008) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med 359: 2456-2467.
47. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet 362: 777-781.
48. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, et al. (2010) Factors Associated with Outcome in Heart Failure with Preserved Ejection Fraction: Findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail In Press.
49. MacDonald MR, Petrie MC, Varyani F, Östergren J, Michelson EL, et al. (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. Eur Heart J 29: 1377-1385.
50. Galderisi M, (2006) Diastolic Dysfunction and Diabetic Cardiomyopathy: Evaluation by Doppler Echocardiography. J Am Coll Cardiol 48: 1548-1551.
51. Fang ZY, Yuda S, Anderson V, Short L, Case C, et al. (2003) Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 41: 611-617.
52. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, et al. (2000) Clinical Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Left Ventricular Filling Pressures: A Comparative Simultaneous Doppler-Catheterization Study. Circulation 102: 1788-1794.
53. Burns AT, Connelly KA, La Gerche A, Mooney DJ, Chan J, et al. (2007) Effect of heart rate on tissue doppler measures of diastolic function. Echocardiography 24: 697-701.
54. Maurer MS, Spevack D, Burkhoff D, Kronzon I, (2004) Diastolic dysfunction: Can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 44: 1543-1549.
55. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG, (2001) Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24: 5-10.
56. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, et al. (2007) Diastolic Heart Failure: Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction. Circulation 115: 888-895.
57. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, et al. (2001) Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 38.
58. Semeniuk LM, Kryski AJ, Severson DL, (2002) Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 283: H976-H982.